6533b823fe1ef96bd127e37d
RESEARCH PRODUCT
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
1 Simona Lattanzi2 Michele Ascoli3 Laura CanafogliaMaria Paola Canevini 4 56 Sara Casciato7 Emanuele Cerulli Irelli4 Valentina Chiesa8 Filippo Dainese9 Giovanni De Maria Giuseppe Didato 106 Giancarlo Di Gennaro Giovanni Falcicchio 117 Martina Fanella Massimo Gangitano 12 Angela La Neve 117 Oriano Mecarelli Elisa Montalenti 137 Alessandra Morano Federico Piazza 14 Chiara Pizzanelli 157 Patrizia Pulitano Federica Ranzato 16 Eleonora Rosati 17 Laura Tassi 187 Carlo Di Bonaventura Brivafirst Group Collaborators Affiliations Collapse Collaborators Brivafirst Group: Angela AlicinoAssenza GiovanniAvorio FedericaBadioni ValeriaBanfi PaolaBartolini Emanuele Luca Manfredi BasiliBelcastro VincenzoBeretta SimoneBerto IreneBiggi MartinaBillo GiuseppeBoero GiovanniBonanni PaoloBongiorno JoleBrigo FrancescoCaggia EmanueleCagnetti ClaudiaCalvello CarmenCesnik EdwardChianale GigliolaCiampanelli DomenicoCiuffini RobertaCocito DarioColella DonatoContento MargeritaCosta CinziaCumbo EduardoD'aniello AlfredoDeleo FrancescoC Difrancesco Jacopo Roberta Di Giacomo Alessandra Di LibertoDomina ElisabettaDonato FrancescoDono FedeleDurante VaniaElia MaurizioEstraneo AnnaEvangelista Giacomo Maria Teresa FaeddaFailli YleniaFallica ElisaFattouch JinaneFerrari AlessandraFlorinda FerreriFisco GiacomoFonti DavideFortunato FrancescoFoschi NicolettaFrancavilla TeresaGalli RositaGasparini SaraGazzina Stefano Anna Teresa Giallonardo Filippo Sean GiorgiGiuliano LorettaHabetswallner FrancescoIzzi FrancescaBenedetta KassabianKiferle LorenzoLabate AngeloLuisi ConcettaMagliani MatteoMaira GiuliaMari LuisaMarino DanielaMascia AddolorataMazzeo AlessandraMeletti StefanoMilano ChiaraNilo AnnacarmenOrlando BiagioPaladin Francesco Maria Grazia PascarellaPastori ChiaraPauletto GiadaPeretti AlessiaPerri GabriellaPezzella MariannaPiccioli MartaPignatta PietroPilolli NicolaPisani Francesco Laura Rosa PisaniPlacidi FabioPollicino PatriziaPorcella VittoriaPuligheddu MonicaQuadri Stefano Pier Paolo QuaratoQuintas RuiRenna RosariaRum Adriana Enrico Michele SalamoneSavastano ErsiliaSessa MariaStokelj DavidTartara ElenaTombini MarioTumminelli Gemma Anna Elisabetta VaudanoViganò IlariaViglietta EmanuelaVignoli AglaiaVillani FlavioZambrelli ElenaZummo Leliasubject
AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartialdescription
The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained seizure freedom was achieved by 142 (14.3%) patients, of whom 72 (50.7%) were seizure-free from Day 1 of BRV treatment. Sustained seizure freedom was maintained for ≥6, ≥9, and 12 months by 14.3%, 11.9%, and 7.2% of patients from the study cohort. Sustained seizure response was reached by 383 (38.5%) patients; 236 of 383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by Day 1, 94 of 383 (24.5%) by Month 4, and 53 of 383 (13.8%) by Month 7 up to Month 12. Adjunctive BRV was associated with sustained seizure frequency reduction from the first day of treatment in a subset of patients with uncontrolled focal epilepsy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-05-01 |